VistaGen Therapeutics, Inc.
News
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
Zacks Investment Research VistaGen Therapeutics, Inc. (VTGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings...\n more…
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.94 per share a year ago. These...\n more…
VistaGen Therapeutics GAAP EPS of -$0.35 beats by $0.06, revenue of $0.08M misses by $0.22M
SeekingAlpha.com: All News VistaGen Therapeutics reports Q1 2025 financial results: GAAP EPS beats by $0.06, revenue misses by $0.22M (-52.9% Y/Y).\n more…
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
Business Wire Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and...\n more…
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research Seer, Inc. (SEER) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.37 per share a year ago. These figures are...\n more…
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.58 per share a year ago. These figures...\n more…